Beta Bionics (BBNX) Competitors

$9.63 -0.19 (-1.93%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$9.55 -0.08 (-0.83%)

As of 06:38 AM Eastern

BBNX vs. ENOV, PRCT, PLSE, INSP, and CDRE

Should you buy Beta Bionics stock or one of its competitors? MarketBeat compares Beta Bionics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Beta Bionics include Enovis (ENOV), PROCEPT BioRobotics (PRCT), Pulse Biosciences (PLSE), Inspire Medical Systems (INSP), and Cadre (CDRE). These companies are all part of the "medical equipment" industry.

How does Beta Bionics compare to Enovis?

Beta Bionics (NASDAQ:BBNX) and Enovis (NYSE:ENOV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Beta Bionics has a beta of 3.29, suggesting that its share price is 229% more volatile than the broader market. Comparatively, Enovis has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Beta Bionics has higher earnings, but lower revenue than Enovis. Beta Bionics is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	4.28	-$73.20M	-$1.51	N/A
Enovis	$2.25B	0.66	-$1.18B	-$19.88	N/A

In the previous week, Enovis had 20 more articles in the media than Beta Bionics. MarketBeat recorded 22 mentions for Enovis and 2 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.67 beat Enovis' score of 0.56 indicating that Beta Bionics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Enovis	8 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Enovis has a net margin of -49.92% compared to Beta Bionics' net margin of -60.27%. Enovis' return on equity of 10.32% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Enovis	-49.92%	10.32%	4.57%

Beta Bionics presently has a consensus price target of $22.00, indicating a potential upside of 128.45%. Enovis has a consensus price target of $45.17, indicating a potential upside of 75.71%. Given Beta Bionics' higher probable upside, equities research analysts clearly believe Beta Bionics is more favorable than Enovis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Enovis	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

98.5% of Enovis shares are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 2.9% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Enovis beats Beta Bionics on 8 of the 15 factors compared between the two stocks.

How does Beta Bionics compare to PROCEPT BioRobotics?

PROCEPT BioRobotics (NASDAQ:PRCT) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

PROCEPT BioRobotics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.29, suggesting that its share price is 229% more volatile than the broader market.

PROCEPT BioRobotics currently has a consensus price target of $41.45, indicating a potential upside of 61.30%. Beta Bionics has a consensus price target of $22.00, indicating a potential upside of 128.45%. Given Beta Bionics' stronger consensus rating and higher possible upside, analysts clearly believe Beta Bionics is more favorable than PROCEPT BioRobotics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 6.6% of PROCEPT BioRobotics shares are held by insiders. Comparatively, 5.3% of Beta Bionics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Beta Bionics has lower revenue, but higher earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	4.75	-$95.57M	-$1.82	N/A
Beta Bionics	$100.25M	4.28	-$73.20M	-$1.51	N/A

In the previous week, PROCEPT BioRobotics had 6 more articles in the media than Beta Bionics. MarketBeat recorded 8 mentions for PROCEPT BioRobotics and 2 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.67 beat PROCEPT BioRobotics' score of 1.12 indicating that Beta Bionics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

PROCEPT BioRobotics has a net margin of -31.82% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
Beta Bionics	-60.27%	-23.00%	-20.55%

Summary

Beta Bionics beats PROCEPT BioRobotics on 9 of the 17 factors compared between the two stocks.

How does Beta Bionics compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Pulse Biosciences has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.29, suggesting that its share price is 229% more volatile than the broader market.

Pulse Biosciences currently has a consensus price target of $30.00, indicating a potential upside of 25.21%. Beta Bionics has a consensus price target of $22.00, indicating a potential upside of 128.45%. Given Beta Bionics' stronger consensus rating and higher possible upside, analysts clearly believe Beta Bionics is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67

76.9% of Pulse Biosciences shares are held by institutional investors. 74.6% of Pulse Biosciences shares are held by insiders. Comparatively, 5.3% of Beta Bionics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pulse Biosciences has higher earnings, but lower revenue than Beta Bionics. Pulse Biosciences is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$751K	2,176.66	-$72.78M	-$1.10	N/A
Beta Bionics	$100.25M	4.28	-$73.20M	-$1.51	N/A

In the previous week, Pulse Biosciences had 12 more articles in the media than Beta Bionics. MarketBeat recorded 14 mentions for Pulse Biosciences and 2 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.67 beat Pulse Biosciences' score of 0.72 indicating that Beta Bionics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	1 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Pulse Biosciences has a net margin of 0.00% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-80.51%	-69.14%
Beta Bionics	-60.27%	-23.00%	-20.55%

Summary

Beta Bionics beats Pulse Biosciences on 10 of the 17 factors compared between the two stocks.

How does Beta Bionics compare to Inspire Medical Systems?

Beta Bionics (NASDAQ:BBNX) and Inspire Medical Systems (NYSE:INSP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

Beta Bionics currently has a consensus price target of $22.00, indicating a potential upside of 128.45%. Inspire Medical Systems has a consensus price target of $85.00, indicating a potential upside of 102.81%. Given Beta Bionics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Beta Bionics is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Inspire Medical Systems	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Beta Bionics has a beta of 3.29, suggesting that its share price is 229% more volatile than the broader market. Comparatively, Inspire Medical Systems has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

In the previous week, Inspire Medical Systems had 9 more articles in the media than Beta Bionics. MarketBeat recorded 11 mentions for Inspire Medical Systems and 2 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.67 beat Inspire Medical Systems' score of 0.69 indicating that Beta Bionics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Inspire Medical Systems	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Inspire Medical Systems has a net margin of 14.33% compared to Beta Bionics' net margin of -60.27%. Inspire Medical Systems' return on equity of 10.35% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Inspire Medical Systems	14.33%	10.35%	8.81%

94.9% of Inspire Medical Systems shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by company insiders. Comparatively, 2.2% of Inspire Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Inspire Medical Systems has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	4.28	-$73.20M	-$1.51	N/A
Inspire Medical Systems	$911.98M	1.32	$145.42M	$4.49	9.33

Summary

Inspire Medical Systems beats Beta Bionics on 9 of the 17 factors compared between the two stocks.

How does Beta Bionics compare to Cadre?

Beta Bionics (NASDAQ:BBNX) and Cadre (NYSE:CDRE) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Cadre has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	4.28	-$73.20M	-$1.51	N/A
Cadre	$610.31M	2.19	$44.14M	$1.07	29.24

Beta Bionics has a beta of 3.29, suggesting that its stock price is 229% more volatile than the broader market. Comparatively, Cadre has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

Beta Bionics presently has a consensus price target of $22.00, suggesting a potential upside of 128.45%. Cadre has a consensus price target of $39.75, suggesting a potential upside of 27.06%. Given Beta Bionics' stronger consensus rating and higher probable upside, research analysts clearly believe Beta Bionics is more favorable than Cadre.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Cadre	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.43

In the previous week, Cadre had 11 more articles in the media than Beta Bionics. MarketBeat recorded 13 mentions for Cadre and 2 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.67 beat Cadre's score of -0.06 indicating that Beta Bionics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cadre	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cadre has a net margin of 5.80% compared to Beta Bionics' net margin of -60.27%. Cadre's return on equity of 11.67% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Cadre	5.80%	11.67%	4.78%

44.0% of Cadre shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by company insiders. Comparatively, 30.1% of Cadre shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Cadre beats Beta Bionics on 10 of the 16 factors compared between the two stocks.

Get Beta Bionics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBNX vs. The Competition

Export

Metric	Beta Bionics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$437.60M	$6.90B	$6.30B	$12.20B
Dividend Yield	N/A	1.72%	2.79%	5.30%
P/E Ratio	-6.38	49.93	21.03	25.58
Price / Sales	4.28	39.65	552.98	78.84
Price / Cash	N/A	24.21	42.94	55.34
Price / Book	1.58	6.49	9.82	6.66
Net Income	-$73.20M	$158.34M	$3.55B	$333.63M
7 Day Performance	-8.29%	-1.83%	-0.53%	-0.11%
1 Month Performance	-18.46%	-1.10%	1.20%	3.94%
1 Year Performance	-25.00%	-2.35%	41.23%	36.07%

Beta Bionics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBNX Beta Bionics	3.6291 of 5 stars	$9.63 -1.9%	$22.00 +128.5%	-27.0%	$437.60M	$100.25M	N/A	294
ENOV Enovis	4.0246 of 5 stars	$26.52 -2.7%	$46.57 +75.6%	-31.3%	$1.53B	$2.25B	N/A	7,802	Earnings Report
PRCT PROCEPT BioRobotics	3.9925 of 5 stars	$25.40 -0.2%	$41.45 +63.2%	-51.5%	$1.45B	$308.05M	N/A	430
PLSE Pulse Biosciences	2.7323 of 5 stars	$19.08 -2.6%	$30.00 +57.2%	+42.3%	$1.30B	$751K	N/A	140	Insider Trade
INSP Inspire Medical Systems	3.8382 of 5 stars	$44.28 -2.8%	$85.00 +92.0%	-73.8%	$1.28B	$915.25M	9.86	1,333

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBNX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Beta Bionics (BBNX) Competitors

BBNX vs. ENOV, PRCT, PLSE, INSP, and CDRE

How does Beta Bionics compare to Enovis?

Summary

How does Beta Bionics compare to PROCEPT BioRobotics?

Summary

How does Beta Bionics compare to Pulse Biosciences?

Summary

How does Beta Bionics compare to Inspire Medical Systems?

Summary

How does Beta Bionics compare to Cadre?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX vs. The Competition

Beta Bionics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Beta Bionics (BBNX) Competitors

BBNX vs. ENOV, PRCT, PLSE, INSP, and CDRE

How does Beta Bionics compare to Enovis?

Which has more volatility and risk, BBNX or ENOV?

Which has preferable earnings & valuation, BBNX or ENOV?

Does the media refer more to BBNX or ENOV?

Is BBNX or ENOV more profitable?

Do analysts prefer BBNX or ENOV?

Do institutionals and insiders believe in BBNX or ENOV?

Summary

How does Beta Bionics compare to PROCEPT BioRobotics?

Which has more risk and volatility, PRCT or BBNX?

Do analysts rate PRCT or BBNX?

Do insiders & institutionals believe in PRCT or BBNX?

Which has better valuation and earnings, PRCT or BBNX?

Does the media prefer PRCT or BBNX?

Is PRCT or BBNX more profitable?

Summary

How does Beta Bionics compare to Pulse Biosciences?

Which has more risk and volatility, PLSE or BBNX?

Do analysts rate PLSE or BBNX?

Do insiders & institutionals believe in PLSE or BBNX?

Which has better valuation and earnings, PLSE or BBNX?

Does the media prefer PLSE or BBNX?

Is PLSE or BBNX more profitable?

Summary

How does Beta Bionics compare to Inspire Medical Systems?

Do analysts prefer BBNX or INSP?

Which has more risk and volatility, BBNX or INSP?

Does the media favor BBNX or INSP?

Is BBNX or INSP more profitable?

Do institutionals & insiders have more ownership in BBNX or INSP?

Which has better valuation and earnings, BBNX or INSP?

Summary

How does Beta Bionics compare to Cadre?

Which has preferable earnings and valuation, BBNX or CDRE?

Which has more volatility & risk, BBNX or CDRE?

Do analysts prefer BBNX or CDRE?

Does the media favor BBNX or CDRE?

Is BBNX or CDRE more profitable?

Do insiders and institutionals have more ownership in BBNX or CDRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX vs. The Competition

Beta Bionics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools